Mumbai: Lupin Limited announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Meclizine Hydrochloride Tablets USP.

The Meclizine Hydrochloride Tablets, 12.5 mg, 25 mg, and 50 mg, to market a generic equivalent of Antivert Tablets, 12.5 mg, 25 mg, and 50 mg, of Casper Pharma LLC, will be manufactured at Lupin’s facility in Goa.

Meclizine Hydrochloride Tablets (RLD Antivert) had an estimated annual sales of USD 29 million in the US.

Other drugs approval by USFDA

USFDA gives nod for Prochlorperazine Maleate Tablets

USFDA gives approval generic Labetalol HCL tablets

USFDA gives final approval for Adapalene and Benzoyl Peroxide Topical Gel

USFDA gives final approval for Empagliflozin tablets

USFDA gives final approval to market this anti-inflammatory skin cream

USFDA grants approval for generic Cyclosporine Soft Gel capsules

Johnson & Johnson to end global sales of talc-based baby powder

USFDA gives nod for Prochlorperazine Maleate Tablets

Possible carcinogen found in some Diabetes drugs: USFDA

USFDA issues Form 483 for 4 observations to Zydus

DCGI notifies classification of 60 Medical Devices related to rehabilitation

Govt reconstitutes National Medical Devices Promotion Council

IPC releases revised draft general chapters on microbiology in IP

USFDA gives approval generic Labetalol HCL tablets

USFDA completes inspection at Stride Pharma with zero observation

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/08/14/usfda-gives-approval-for-meclizine-hcl-tablets/